1. At a Glance – Small Cap Pharma With Big Mood Swings
₹293 crore market cap.
₹124 current price.
-31.7% return in last 3 months.
Stock P/E at 25.6 vs industry P/E 28.5.
ROCE 8.34%. ROE 7.69%.
Debt ₹32.4 crore. Debt/Equity 0.36.
And then boom — Q3 FY26 PAT up 91.67% YoY.
Welcome to Bafna Pharmaceuticals Ltd, a company that behaves like a student who studies one night before the exam and still manages to pass.
Latest quarterly numbers show ₹38.29 crore sales and ₹1.84 crore profit for December 2025 quarter. EPS at ₹0.78 for the quarter. Exports contribute 77% of revenue. Promoters hold 75%. FIIs recently entered with ~9.34%.
It is profitable.
It is exporting globally.
It has 336 licensed formulations.
But ROE is still below 8%.
So the question is simple — is this a quietly improving export pharma story, or just another smallcap that survives quarter to quarter?
Let’s open the medical file.
2. Introduction – Pharma With Passport Stamps
Incorporated in 1981, Bafna Pharmaceuticals is not new to the game. This is not a startup experimenting with herbal detox tablets. This is a 40+ year old pharma manufacturer making finished formulations.
They manufacture over 336 licensed formulations and have globally registered 78 products. That’s not small.
Exports form 77% of FY23 revenue. Countries include UK, Australia, Sri Lanka, Nigeria, Ethiopia, Peru, Zambia and more. Basically, if a country imports generic medicine, Bafna probably has sent a carton there.
Revenue mix FY23:
- Sale of products ~96%
- Analytical income ~1%
- Forex gain ~2%
- Freight income ~1%
So yes, this is a pure formulation play.
But before we clap, remember something.
This company had:
- Flood disruption due to cyclone Michaung (Dec 2023)
- Equipment breakdown (June 2024)
- Sale of manufacturing unit to Navron Pharma (Aug 2024)
- GST demands disclosed in Feb 2026
- Pending litigations ₹4.43 crore (mostly income tax)
This is not a smooth highway story. This is more like Chennai roads during monsoon.
Still reading? Good. Because now it gets interesting.
3. Business Model – WTF Do They Even Do?
Let’s simplify.
They manufacture finished pharmaceutical formulations. Not APIs. Not discovery drugs. Not biotech moonshots.
They make:
- Solid oral dosage forms
- Liquid oral dosage forms
- Betalactam
- Non-betalactam
- Cephalosporin products
- Afenac-P Tab
- Afenac-TH Tab
Think generic tablets. Capsules. Antibiotics. Everyday medicines.
They are basically a contract manufacturer + exporter of generic formulations.
No breakthrough cancer drug.
No patented molecule.
No R&D drama.
Just volume-driven export business.
Now here’s the catch.
